What are the precautions for taking Tafasitamab?

In the clinical study of tafasitamab (Tafasitamab) combined with lenalidomide in the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), warnings and precautions such as infusion-related reactions, bone marrow suppression, infection, embryo-fetal toxicity, etc. occurred. Doctors need to interrupt or stop tafasitamab according to the severity of adverse events.

1. Infusion-related reactions: In clinical studies, 6% of 81 patients experienced infusion-related reactions. 80% of infusion-related reactions occur in cycle 1 or 2. Signs and symptoms include fever, chills, rash, flushing, difficulty breathing, and high blood pressure. These reactions are managed by temporarily interrupting the infusion and/or using supportive medications. Administer patient before starting talfaracetam infusion. Monitor the patient frequently during infusion.

2. Bone marrow suppression: including neutropenia, thrombocytopenia and anemia. In L-MIND, grade 3 neutropenia occurred in 25% of patients, thrombocytopenia in 12%, and anemia in 7%. Grade 4 neutropenia occurred in 25% and thrombocytopenia in 6%. Neutropenia led to treatment discontinuation in 3.7% of patients. Monitor complete blood counts before dosing and throughout each treatment cycle. Monitor patients with neutropenia for signs of infection. Consider the use of granulocyte colony-stimulating factor.

3. Infection: Patients developed fatal and serious infections, including opportunistic infections, during treatment with tafasitamumab and after the last dose. The most common infections are respiratory tract infections, urinary tract infections, bronchitis, nasopharyngitis and pneumonia. The patient is asked for signs and symptoms of infection and the infection is managed as appropriate.

4. Embryo-fetal toxicity: According to its mechanism of action, tafasitamumab may cause fetal B cell depletion when used in pregnant women. Inform pregnant women of potential risks to the fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with talfaracetam and for at least 3 months after the last dose. Tafaracetamab was initially administered in combination with lenalidomide. The combination of tafracetamumab and lenalidomide is contraindicated in pregnant women because lenalidomide can cause birth defects and death.

Talfaracetam's single-origin generic drug has not yet been launched in the country, so it is not included in medical insurance. There are European and American versions of Tafaracetam's single-antigen drugs marketed overseas. The American version's specificationsThe price per box of 200 mg may be around 20,000 yuan, and the price of the European version's 200 mg box may be around 10,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same, but the price is more expensive. Currently, there is no generic version of Tafaracetam on the market. For more drug information and specific prices, please consult a medical consultant.